

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

B 97

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 May 2001 (25.05.2001)

PCT

(10) International Publication Number
WO 01/36489 A2

(51) International Patent Classification: C07K 19/00

12 Avon Place, Cambridge, MA 02140 (US). GILLIES,
Stephen; 159 Sunset Road, Carlisle, MA 01741 (US).

(21) International Application Number: PCT/EP00/10843

(22) International Filing Date:
3 November 2000 (03.11.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/164,855 12 November 1999 (12.11.1999) US

(71) Applicant: MERCK PATENT GMBH [DE/DE]; Frank-
furter Strasse 250, 64293 Darmstadt (DE).

(81) Designated States (*national*): AE, AL, AM, AT, AU, AZ,
BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK,
DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT,
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA,
UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— Without international search report and to be republished
upon receipt of that report.

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(72) Inventors: HARTMANN, Arno; Westring 6, 64354
Reinheim (DE). BRANDT, Silke; Adelnungstrasse 35,
64283 Darmstadt (DE). RIEKE, Erwin; Hermannstrasse
12, 64342 Seeheim (DE). SOBEL, Cornelius; An der
Kirche 4, 99130 Mainz (DE). LO, Kin-Ming; 6 Carol
Lane, Lexington, MA 02420 (US). WAY, Jeffrey, C.;



WO 01/36489 A2

(54) Title: ERYTHROPOIETIN FORMS WITH IMPROVED PROPERTIES

(57) Abstract: The invention relates to novel modified erythropoietin (EPO) forms such as fusion proteins comprising a Fc portion of an Ig molecule and a target molecule having the biological activity of EPO. By selective altering of the amino acid sequences of the erythropoietin moiety as well as of the immunoglobulin moiety and the glycosylation pattern of erythropoietin fusion proteins with enhanced biological activity can be obtained. The invention relates also to novel non-fused EPO molecules which have a pattern of cysteines or disulfide bonding which is distinct from human or animal EPO.

Erythropoietin Forms with Improved Properties

Field of the invention

The present invention relates to novel erythropoietin forms such as fusion
5 proteins comprising a Fc portion of an Ig molecule and a molecule having the
biological activity of erythropoietin (EPO). By selective altering of the amino acid
sequences of the erythropoietin moiety as well as of the immunoglobulin moiety
and the glycosylation pattern of erythropoietin, fusion proteins (Fc-EPO) and non-
fused EPO with improved properties, e.g. enhanced biological activity and
10 stability, can be obtained. Furthermore, fusion proteins can be provided, wherein
shortened versions of erythropoietin and the immunoglobulin chain are used. The
invention relates also to novel (non-fused) EPO molecules which have a pattern
of cysteines and disulfide bonding which is distinct from human or animal EPO.

15 Background

Erythropoiesis, the production of red blood cells, occurs continuously throughout
the human life span as a compensation for cell destruction. Erythropoiesis is a
precisely controlled physiological mechanism enabling sufficient numbers of red
blood cells to be available in the blood for proper tissue oxygenation, but not so
20 many that the cells would impede circulation. The maturation of red blood cells is
under the control of the hormone, erythropoietin (EPO).

Erythropoietin is a acidic glycoprotein hormone of approximately 34,000 daltons.
Naturally occurring erythropoietin is produced by the liver during fetal life and by
25 the kidney in response to hypoxia (e.g., red blood cell loss due to anemia) and
regulates red blood cell growth and differentiation through interaction with its
cognate cellular receptor cells into erythrocytes. It is essential for regulating levels
of red blood cells in blood circulation of adults and stimulates the production of
red blood cells in bone marrow. Anemia is a consequence of renal failure to
30 produce erythropoietin. Recombinant erythropoietin produced by genetic
engineering techniques involving the expression of a protein product from a host
cell transformed with the gene encoding erythropoietin has been found to be
effective when used in the treatment of anemia resulting from chronic renal
failure. Wild type, or naturally-occurring, erythropoietin is defined herein to include

recombinant erythropoietin (Jacobs, K., *et al.*, *Nature*, 313:806-813 (1985)), or naturally-occurring erythropoietin which has been isolated and purified from blood (Miyake, T., *et al.*, *J. Biol. Chem.*, 252:5558-5564 (1977)) or sheep plasma (Goldwasser, E., *et al.*, *Proc. Natl. Acad. Sci. U.S.A.*, 68:697-698 (1971)), or

5 chemically synthesized erythropoietin which can be produced using techniques well known to those of skill in the art. Human erythropoietin is a 166 amino acid polypeptide that exists naturally as a monomer (Lin, F-K., *et al.*, *Proc. Natl. Acad. Sci. USA* 82:7580-7584 (1985)). The tertiary structure of erythropoietin as an isolated protein and in a complex with its receptor has been reported (Syed RS,

10 *et al.*, *Nature* [1998] 395:511-6; Cheetham JC, *Nat Struct Biol.* [1998] 5:861-6). The identification, cloning, and expression of genes encoding erythropoietin are described in U.S. patent 4,703,008. A description of the purification of recombinant erythropoietin from cell medium that supported the growth of mammalian cells containing recombinant erythropoietin plasmids for example, is

15 included in U.S. patent 4,667,016. The expression and recovery of biologically active recombinant erythropoietin from a mammalian cell containing the erythropoietin gene on a recombinant plasmid has, made available quantities of erythropoietin suitable for therapeutic applications. In addition, knowledge of the gene sequence and the availability of larger quantities of purified protein has led

20 to a better understanding of the mode of action of this protein. Several forms of anemia, including those associated with renal failure, HIV infection, blood loss and chronic disease can be treated with this hematopoietic growth factor. Erythropoietin is typically administered by intravenous or subcutaneous injection three times weekly at a dose of approximately 25-100

25 U/kg.

Unlike proteins from prokaryotic cells, many cell surface and secretory proteins produced by eukaryotic cells are modified with one or more oligosaccharide groups. This modification, referred to as glycosylation, can dramatically affect the

30 physical properties of proteins and can also be important in protein stability, pharmacokinetics, secretion, and subcellular localization. Proper glycosylation can be essential for biological activity. In fact, some genes from eukaryotic organisms, when expressed in bacteria (e.g., *E. coli*) which lack cellular processes for glycosylating proteins, yield proteins that are recovered with little or

no activity by virtue of their lack of glycosylation. Glycosylation occurs at specific locations along the polypeptide backbone and is usually of two types: O-linked oligosaccharides are attached to serine or threonine residues while N-linked oligosaccharides are attached to asparagine residues when they are part of the sequence Asn-X-Ser/Thr, where X can be any amino acid except proline. The structures of N-linked and O-linked oligosaccharides and the sugar residues found in each type are different. One type of sugar that is commonly found on both is N-acetylneuraminic acid (hereafter referred to as sialic acid). Sialic acid is usually the terminal residue of both N-linked and O-linked oligosaccharides and, by virtue of its negative charge, may confer acidic properties to the glycoprotein.

Human recombinant erythropoietin (expressed in mammalian cells) contains three N-linked and one O-linked oligosaccharide chains which together comprise about 40% of the total molecular weight of the glycoprotein. N-linked glycosylation occurs at asparagine residues (Asn) located at positions 24, 38 and 83 while O-linked glycosylation occurs at a serine residue (Ser) located at position 126 (Lai et al. J. Biol. Chem. 261, 3116 (1986); Broudy et al. Arch. Biochem. Biophys. 265, 329 (1988)). The oligosaccharide chains have been shown to be modified with terminal sialic acid residues. EPO isoforms having a modified sialic acid pattern are disclosed e.g. in EP 0668 351 or EP 0428 267.

Glycosylation does not seem to be essential for activity, because enzymatically deglycosylated erythropoietin has an activity similar to that of the normally glycosylated protein. However, when the glycosylation sites in erythropoietin are mutated to prevent glycosylation, there is a profound inhibition of the normal synthesis and export of the protein (Dube et al., JBC [1988] 263:17516). Specifically, elimination of glycosylation at Asn₃₈ causes a 99% synthesis block, and elimination of glycosylation at Asn₈₃ causes at least a 99.99% synthesis block, and elimination of glycosylation at Ser₁₂₆ causes a 99.8% synthesis block.

One problem with erythropoietin therapy is that, although quite effective, this form of therapy is very expensive. Another problem encountered in the practice of medicine when using injectable pharmaceuticals is the frequency at which those injections must be made in order to maintain a therapeutic level of the compound in the circulation. For example, erythropoietin has a relatively short plasma

half-life (Spivak, J.L., and Hogans, B.B., *Blood*, 73:90 (1989); McMahon, F.G., et al., *Blood*, 76:1718(1990)), therefore, therapeutic plasma levels are rapidly lost, and repeated intravenous administrations must be made.

- 5 It would be advantageous to have available derivatives of erythropoietin which have an extended circulating half-life to avoid such problems. In addition one would prefer to synthesize EPO in a host cell other than a mammalian cell. Unfortunately, synthesis in bacteria is problematic because the protein is not produced in a properly folded, native conformation. Synthesis in insect cells or
- 10 plant cells is also problematic because these cells provide an unfavorable glycosylation pattern. Proteins that are glycosylated according to the insect pattern or the plant patterns are, upon injection into animals, generally taken up by specific receptors and rapidly degraded. For example, macrophages in the liver possess high mannose receptors and asialo-glycoprotein receptors that
- 15 remove proteins with non-mammalian glycosylation patterns.

Summary of the invention

- The invention provides novel modified EPO forms, above all fusion proteins but
- 20 also non-fused EPO modifications, with surprising activities that address the above-said problems.

- Fusion proteins and modification of specified fusion proteins are known in the art. For example, fusion proteins may effectively block a proteolytic enzyme from
- 25 physical contact with the protein backbone itself, and thus prevent degradation. Additional advantages include, under certain circumstances, improved yield in a specific expression system, correct folding of a target protein, and increasing the stability, circulation time, and the biological activity of the therapeutic protein.
- One such modification is the use of the Fc region of immunoglobulins. Antibodies
- 30 comprise two functionally independent parts, a variable domain known as "Fab", which binds antigen, and a constant domain, known as "Fc" which provides the link to effector functions such as complement or phagocytic cells.
- The Fc portion of an immunoglobulin mediates a long plasma half life when fused to certain proteins that have particularly short half lives, whereas the mere Fab

fragment is short-lived. Capon, et al., Nature 337: 525-531 (1989). For example, IL-10, an anti-inflammatory and anti-rejection agent has been fused to the N-terminus of murine Fc γ 2a in order to increase the cytokine's short circulating half-life (Zheng, X. et al., The Journal of Immunology, 154: 559C-5600 (1995)).

5 In addition, the N-terminus of interleukin 2 has also been fused to the Fc portion of IgG1 or IgG3 to overcome the short half life of interleukin 2 and its systemic toxicity (Harvill et al., Immunotechnology, 1: 95-105 (1995)). IL-10 and IL-2, unlike EPO, are small proteins that have very short serum half-lives because they are rapidly cleared by renal filtration.

10

Therapeutic fusion proteins have also been constructed using the Fc domain to incorporate functions such as Fc receptor binding, protein A binding, complement fixation and placental transfer which all reside in the Fc proteins of immunoglobulins. For example, the Fc region of an IgG1 antibody has been fused
15 to the N-terminal end of CD30-L, a molecule which binds CD30 receptors expressed on Hodgkin's Disease tumor cells, anaplastic lymphoma cells, T-cell leukemia cells and other malignant cell types (U.S. Patent No. 5,480,981). Furthermore, it has been reported in 1996 that efficient expression and secretion of certain non-mutant target proteins can be achieved by expression of fusion
20 proteins comprising an Fc portion of an immunoglobulin and said target proteins followed by proteolytic cleavage of the target protein (WO 96/08570, US 5,541,087).

The invention presents novel proteins that have erythropoietin-like activity in their
25 ability to stimulate production of red blood cells in an animal, but with additional advantageous properties such as increased activity, the ability to be synthesized without glycosylation and longer serum half-life. These novel proteins include mutated versions of EPO which are not fused to other proteins, fusion proteins of EPO to immunoglobulin regions, forms of EPO with altered glycosylation, forms
30 of EPO that usefully combine mutation, fusion to other moieties, and/or altered glycosylation, forms of EPO that have a truncated amino acid sequence, forms of Fc immunoglobulin portions which are modified / mutated having herewith a reduced affinity e.g. to Fc receptors, shortened or truncated forms of Fc and Fc-EPO constructs having specific linkers.

The EPO forms as defined above and below such as Fc-EPO fusion proteins of this invention show improved properties such as enhanced biological activity and improved stability.

5 Detailed Description

It is an object of the present invention to provide a modified erythropoietin (EPO) form having improved properties, wherein said EPO form can be either a non-fused human or mammalian modified EPO having the pattern of cysteines or
 10 disulfide bonds that differs from the disulfide bonding or cysteine pattern of human or mammalian EPO, or a fusion protein comprising a Fc portion of an Ig molecule and an erythropoietin molecule (EPO), wherein said Fc portion is fused covalently via its C-terminus directly or indirectly to said EPO molecule by its N-terminus and wherein the Fc portion as well as the EPO portion may be modified
 15 or mutated, selected from the group:

- (i) Fc - EPO
- (ii) Fc - L - EPO
- (iii) Fc - EPO_{desial}
- (iv) Fc - EPO_m
- 20 (v) Fc_m - EPO
- (vi) Fc_m - EPO_m
- (vii) Fc_m - L - EPO
- (viii) Fc - L - EPO_m
- (ix) Fc - EPO_{trunc}
- 25 (x) Fc - L - EPO_{trunc}

Herein, EPO has the meaning of naturally occurring EPO from mammalian, preferably human origin and includes also recombinant EPO engineered from natural sources. This EPO according to the invention is glycosylated, non-
 30 glycosylated, partially glycosylated or otherwise modified in its glycosylation pattern as indicated above, below and in the prior art. For certain uses, the EPO moiety has a correctly folded structure. The invention discloses novel methods for synthesizing forms of EPO that are unglycosylated. Previously, it was known that glycosylated EPO could be treated with N-glycosidase, which removes sugar

groups that are attached to asparagine. However, this enzyme does not remove the distinct sugar modification that is found on Ser₁₂₆. As a general alternative method of synthesis, it is possible to express EPO in bacteria, where no glycosylation will occur. However, proteins synthesized by this method generally are obtained as denatured proteins in inclusion bodies, and do not have disulfide bonds. Thus, additional effort is required to reconstitute the protein into a soluble state. Finally, mutation of the glycosylation sites in EPO results in a protein that cannot be synthesized in mammalian cells (Dube et al., JBC [1988] 263:17516). It appears that the mutant protein is degraded before it can be secreted.

However, as disclosed herein, when DNA constructs encoding Fc-unglycosylated EPO are placed in mammalian cell lines, the Fc-unglycosylated EPO is efficiently expressed, secreted, and found in a soluble form in the culture supernatant. The Fc-unglycosylated EPO fusion protein can be purified by standard techniques, for example, on a protein A column. For example, the Fc-unglycosylated EPO can be injected into animals as an antigen to raise antibodies that are directed against the novel epitopes revealed by the absence of glycosylation. In addition, the Fc-unglycosylated EPO, containing only mutations at the glycosylation sites, has detectable EPO activity and can be used as a starting point for the isolation of additionally mutated forms that have increased activity.

EPO_{desial} is a glycosylated EPO according to the invention, wherein sialic acid residues that are normally found on a secreted, glycosylated protein are partially or substantially absent. This can be achieved by enzymatically treatment with an enzyme such that the sialic acid residues have been substantially removed. For example, a protein that is treated with the enzyme neuraminidase will have its sialic acids removed. Such a protein is also recognized by the asialoglycoprotein receptor in the liver. A desialylation can also be achieved by using mutated cells which are deficient in enzymes responsible for this step. For example, the known Lec-2 mutant derivative of the CHO cell line is defective in addition of sialic acid residues to N-linked and O-linked sugar chains in secreted proteins ("asialo"). As a result, the exposed galactose residue on such proteins can be recognized by the asialoglycoprotein receptor in the liver, taken up into cells, and is usually degraded. The desialylation in the EPO moiety of the fusion proteins according to the invention does not need to be completely removed.

EPO_{trunc} is an EPO according to this invention which is truncated but not mutated in its amino acid sequence. Truncated forms are protein fragments having essentially the full or only a slightly reduced biological activity of erythropoietin.

Preferred truncated forms of EPO according to this invention are shortened at the

5 C-terminus and have at least 65 amino acids calculated from the N-terminal.

Preferred truncated EPO forms have 155 – 116, 108, 104, 98, 93, 88, 85 or 78 amino acids. Especially preferred forms of EPO ends C-terminally with amino acid positions 108, 104, 98, 93, 88, 85 or 78.

10 The Fc region of an immunoglobulin is the amino acid sequence for the carboxyl-terminal portion of an immunoglobulin heavy chain constant region. The Fc regions are particularly important in determining the biological functions of the immunoglobulin and these biological functions are termed effector functions. As known, the heavy chains of the immunoglobulin subclasses comprise four or five

15 domains: IgM and IgE have -five heavy chain domains, and IgA, IgD and IgG have four heavy chain domains. The Fc region of IgA, IgD and IgG is a dimer of the hinge-CH₂-CH₃ domains, and in IgM and IgE it is a dimer of the hinge-CH₂-CH₃-CH₄ domains (see, W.E.Paul, ed., 1993, Fundamental Immunology, Raven Press, New York, New York).

20

As used herein, the term "Fc portion of an Ig molecule" means the carboxyl-terminal portion of an immunoglobulin heavy chain constant region, or an analog or portion thereof. That is, e.g., an immunoglobulin Fc region of Ig, preferably IgG, most preferably IgG1, IgG2 and IgG3, may comprise at least a portion of a

25 hinge region, a CH₂ domain, and a CH₃ domain. In a preferred embodiment the Fc region includes at least a portion of a hinge region and a CH₃ domain.

In some circumstances, it is useful to mutate certain amino acids within the Fc moiety of an Fc-EPO fusion protein. For example, if an Fc-EPO fusion protein is

30 to be expressed in a cell type that generates a non-human glycosylation pattern, it is often useful to mutate the glycosylation site within the Fc region and thus entirely eliminate glycosylation at this site. As a result, the resulting protein will not be identified and degraded by scavenging systems that recognize altered glycosylation patterns.

Thus, Fc_m is a Fc portion as defined above which is mutated and / or truncated in its amino acid sequence and / or modified in its glycosylation pattern. It has been shown by this invention that such modified Fc portions lead to Fc-EPO fusion proteins with improved properties. In this context Fc_m includes additionally

5 modified or mutated Fc portions which have a reduced affinity to Fc receptors on cells. The binding affinity of fusion proteins for Fc receptors can be reduced by using heavy chain isotypes as fusion partners that have per se diminished binding affinity for Fc receptors on cells. For example, it is known that, for example, IgG1 and IgG3 bind to $Fc\gamma R1$ with high affinity and that the binding sites

10 are located in the CH2 domain. Thus, it is an object of the invention to provide a Fc-EPO fusion protein with enhanced in vivo circulating half-life having a mutation, deletion or insertion at one or more amino acids in the domains responsible for Fc receptor binding. In a preferred embodiment of the invention the Fc-EPO fusion protein comprises a Fc portion of an IgG1, wherein said

15 mutations, deletions, or insertions in the IgG1 constant region are selected from Leu₂₃₄, Leu₂₃₅, Gly₂₃₆, Gly₂₃₇, Asn₂₉₇, and Pro₃₃₁. In an alternative preferred embodiment the mutation, deletion or insertion is introduced in the IgG1 constant region of a Fc portion of a fusion protein according to the invention at one or more amino acids selected from Leu₂₈₁, Leu₂₈₂, Gly₂₈₃, Gly₂₈₄, Asn₃₄₄ and Pro₃₇₈.

20 Methods for making Fc portions with reduced Fc receptor affinity are, for example, disclosed in PCT/US99/03966.

The invention also discloses methods for generating useful mutant forms of Fc-EPO in which the EPO moiety is altered. Variants of Fc-EPO with increased EPO

25 biological activity can be generated by procedures described in the Examples and known in the art.

Thus, EPO_m is an EPO according to this invention which is mutated but not truncated in its amino acid sequence. The number of mutations is not limited but is restricted to the loss of the biological activity of the molecule. Preferably

30 mutations of 1 to 10 amino acids are used. Surprisingly it could be shown that the Fc fusion proteins according to the invention, wherein EPO is mutated as defined above, have greater specific activity than the comparable Fc-EPO fusion proteins having no mutated EPO moieties. Therefore, it is an preferred object of the invention to provide Fusion proteins as defined above and in the claims, wherein

EPO is mutated. Preferred fusion proteins of this invention have an EPO molecule, wherein in the EPO_m portion at least one of the following changes are achieved: Asn_{24, 38, 83} → Xxx, Ser₁₂₅ → Xxx, where Xxx is a different amino acid. Preferred changes according to the invention are Asn_{24, 38, 83} → Gln and / or Ser₁₂₅ → Ala. Further preferred mutations are: His 32 → Gly and / or Ser 34 → Arg and / or Pro 90 → Ala. In one embodiment of the invention all above-said mutations are achieved.

These and other variant proteins according to the invention may enhance binding to the EPO receptor, enhanced stability, enhanced adoption of a correct, active conformation, enhanced pharmacokinetic properties, enhanced synthesis, or other advantageous features. Mutations in the EPO moiety of Fc-EPO can be combined to generate proteins that have further enhanced activities.

A specific method for improvement of Fc-EPO disclosed in the Examples uses site-directed mutagenesis techniques. It is important to note that a wide variety of site-directed mutagenesis techniques are available, and can be used as alternatives to achieve similar results. The strategies for choosing among these techniques is well-known to those skilled in the art of molecular biology.

Similarly, there is a wide variety of techniques for achieving random and semi-random mutagenesis of a target DNA. These techniques are also well-known to those skilled in the art of molecular biology.

Additional mutant forms of Fc-EPO may be constructed according to this invention. The mutations have the effect of increasing the activity of unglycosylated Fc-EPO. Depending on the mutation, activity is increased by a variety of mechanisms, such as increasing affinity of Fc-EPO for the EPO receptor, increasing the fraction of Fc-EPO that is properly folded, or improving the pharmacokinetic properties of Fc-EPO. Some mutations, when combined, have an additive or multiplicative effect on the activity of unglycosylated Fc-EPO.

The Fc portion and the EPO proteins according to this invention may also be linked by linker molecules, wherein the chemical or amino acid linkers are of varying length. The chemical linkers are well known in the art. Peptide linkers are

preferred. Fusion proteins, wherein the Fc portion is linked with the target protein by a linker molecule may have improved properties. The Fc- EPO fusion proteins according to the invention having such linker molecules show an enhanced biological activity. The linker of the invention (L) is a linker molecule as defined

5 above and below which has no protease cleavage site.

The peptide linker often is a series of peptides such as. e.g., glycine and/or serine. Preferably, the peptide linker is a mixed series of glycine and serine peptides about 5 - 25, preferably 10 - 20 residues in length.

Preferred amino acid linkers L are used and include the following sequences,

10 wherein such linkers are excluded that possess a cleavage site for proteolytic enzymes:

1. Ala Ala Ala
2. Ala Ala Ala Ala,
3. Ala Ala Ala Ala Ala,
- 15 4. Ser,
5. Ser Ser,
6. Gly Gly Gly,
7. Gly Gly Gly Gly,
8. Gly Gly Gly Gly Gly,
- 20 9. Gly Gly Gly Gly Gly Gly Gly,
10. Gly Pro Gly,
11. Gly Gly Pro Gly Gly,
12. Gly Gly Gly Gly Ser, and
13. any combinations of subparts 1-12

25 Preferred amino acid linkers are (Gly Gly Gly Gly Ser)_x wherein x is 1-5.

Additional suitable linkers are disclosed in Robinson et al., 1998, Proc. Natl. Acad. Sci. USA; 95, 5929.

As used herein, "proteolytic cleavage site" means amino acid sequences which
30 are preferentially cleaved by a proteolytic enzyme or other proteolytic cleavage agents. Proteolytic cleavage sites include amino acids sequences which are recognized by proteolytic enzymes such as trypsin, plasmin or enterokinase K. Many cleavage site/cleavage agent pairs are known. Where the target protein sequence is a precursor molecule to Interferon-alpha or an active variant thereof,

the desired protein product may be produced by cleavage with the endogenous proteolytic enzyme, such as elastin or plasmin or urokinase.

As used above and below, the biological activity of erythropoietin and EPO fusion proteins, respectively, is defined as the ability to regulate red blood cell growth and differentiation through interaction with its cognate cellular receptor, or the antigenic property of inducing a specific immunological response as determined using well-known laboratory techniques. For example, a biologically active, or functionally active, fragment of erythropoietin (EPO_{trunc}) can induce an immunological response which produces antibodies specific for erythropoietin (anti-erythropoietin antibodies).

To be "functionally" or "biologically active" an erythropoietin-like molecule, such as Fc-EPO, typically shares substantial sequence (amino acid) similarity (e.g., at least about 65%, typically at least about 80% and most typically about 90 - 95%) with the corresponding sequences of wild type, or naturally-occurring, erythropoietin and possesses one or more of the functions of wild type erythropoietin thereof.

As pointed out above the fusion proteins of the present invention have improved properties. Thus, they show improved biological activity and have an extended serum half-life, wherein said extended serum half-life is greater than 15 hours, preferably greater than 20 hours, most preferably greater than 25 hours.

Another and important aspect of this invention is the finding that in order to get improved EPO forms, preferably Fc-EPO fusion proteins, it is advantageous to introduce altered patterns of cysteine-cysteine disulfide bonds. Thus, it is an object of the invention to provide Fc-EPO fusion proteins or non-fused EPO, wherein at least one, preferably 2 - 4 cystein residues of the EPO or EPO_m moiety are engineered. Especially, it is an object of the invention to provide Fc-EPO fusion proteins or non-fused EPO, wherein the EPO or EPO_m moiety has a pattern of disulfide bonding which is distinct from human or mammalian EPO. In one embodiment of the invention the EPO moiety includes one or more of the following amino acid variations: position 29 is not Cys, position 33 is not Cys, position 88 is Cys and position 139 is Cys. In a preferred Cys - engineered

embodiment of this invention the EPO moiety is derived from human EPO and has at least one of the following mutations: His 32 → Gly, Ser 34 → to Arg and Pro 90 → Ala.

To generate an altered disulfide bond, one cysteine residue is mutated to a structurally compatible amino acid such as alanine or serine, and a second amino acid that is nearby in the three-dimensional structure is mutated to cysteine.

Thus, it is a further object of this invention to provide FC-EPO fusion proteins or non-fused EPO, wherein at least one of the cysteine residues of the EPO molecule or EPO_m molecule is engineered by techniques which are well known in

the art. One embodiment is a Fc-EPO fusion protein, wherein Cys₃₃ is replaced by any other amino acid. In an alternative embodiment a fusion protein is object of the invention, wherein one of the amino acids Gln₈₆, Pro₈₇, Trp₈₈, Glu₈₉, Leu₉₁ is replaced by Cys. Preferably, Trp₈₈ is replaced by Cys. For example, a fusion protein containing an EPO moiety lacking Cys at position 33 and containing Cys at position 88 will form a disulfide bond that is not found in human EPO. This bond results in a fusion protein that has superior properties to an otherwise similar fusion protein containing a disulfide bond between Cys₂₉ and Cys₃₃. For example, the Cys₂₉-Cys₈₈ fusion protein has greater activity than the Cys₂₉-Cys₃₃ fusion protein. In addition, the Cys₂₉-Cys₈₈ fusion protein shows a pronounced increase in activity, relative to the Cys₂₉-Cys₃₃ fusion protein, in the presence of other mutations in the EPO moiety of the fusion protein. It is also sometimes useful to incorporate the mutations His₂₂ to any other amino acid, preferably Gly or Ser, mutation of Ser₃₄ to Arg, and mutation of Pro₉₀ to Ala.

Another useful set of mutations includes mutation of Cys₂₉ of the EPO of the invention to any other amino acid, and mutation of Arg₁₃₉ to Cys. An EPO form containing both of these mutations will generally contain a disulfide bond between Cys₃₃ and Cys₁₃₉. This bond results in a fusion protein that has superior properties to an otherwise similar fusion protein containing a disulfide bond between Cys₂₉ and Cys₃₃. For example, the Cys₃₃-Cys₁₃₉ fusion protein has greater activity than the Cys₂₉-Cys₃₃ fusion protein. In addition, the Cys₃₃-Cys₁₃₉ fusion protein shows a pronounced increase in activity, relative to the Cys₂₉-Cys₃₃

fusion protein, in the presence of other mutations in the EPO moiety of the fusion protein.

As a further alternative, an entirely new disulfide bond is added to the protein by mutating two amino acids to cysteines.

5

It is known in the art that erythropoietin synthesized by non-human animals generally contains a different pattern of cysteine residues than human erythropoietin (Wen, D., et al. Erythropoietin structure-function relationships: high degree of sequence homology among mammals *Blood* 82, 1507-1516 [1993]; Fu, P., et al. The sheep erythropoietin gene: molecular cloning and effect of hemorrhage on plasma erythropoietin and renal/liver messenger RNA in adult sheep *Mol. Cell. Endocrinol.* 93, 107-116 [1993]; Lin, F.K., et al., Monkey erythropoietin gene: cloning, expression and comparison with the human erythropoietin gene *Gene* 44, 201-209 [1986]; Suliman, H.B., et al. Cloning of a cDNA encoding bovine erythropoietin and analysis of its transcription in selected tissues *Gene* 171, 275-280 (1996) ; McDonald, J.D., Cloning, sequencing, and evolutionary analysis of the mouse erythropoietin gene *Mol. Cell. Biol.* 6, 842-848 [1986]; Nagao, M., et al. Nucleotide sequence of rat erythropoietin *Biochim. Biophys. Acta* 1171 (1), 99-102 [1992]). However, the erythropoietin normally produced by most of these animals, such as macaques, pigs, dogs, cats, cows, and sheep, contains five cysteines. Rodents such as mice and rats have four cysteines, but the two of the cysteines are at positions 29 and 139. Based on the three-dimensional structure of human EPO, the cysteines of rodent EPO at positions 29 and 139 are unable to form disulfide bonds with each other or any of the other cysteines. In general, secreted extracellular proteins do not contain unpaired cysteines. In the relatively oxidizing environment of the extracellular space, unpaired cysteines may be oxidized, for example, to cysteic acid. As a result, the activity of the protein may be reduced. Without wishing to be bound by theory, the oxidation of cysteines in the EPO of non-human animals may serve to down-regulate EPO activity, inactivating the EPO protein in conditions of high oxygen when erythropoiesis is not needed.

30

In any case, the invention provides EPO moieties that are distinct from known animal-derived forms of EPO in that they have an even number of cysteines and

all of the cysteines are capable of forming disulfide bonds. These EPO moieties containing novel disulfide bonding patterns may be useful as Fc fusions, as fusions to other proteins such as albumin, or as unfused, isolated moieties.

- 5 Another feature of the invention is a form of EPO with cysteines at positions 29, 33, 88, and 139. When this set of cysteines is present in an EPO that contains the usual cysteines at positions 7 and 161, the resulting EPO contains three disulfide bonds instead of two. The resulting molecule is extremely stable, even in the presence of other mutations that destabilize the normal EPO protein. For
- 10 example, EPO (Cys₂₉-Cys₈₈, Cys₃₃-Cys₁₃₉) is much more stable than normal human EPO. Similarly, fusion proteins such as Fc fusions to EPO (Cys₂₉-Cys₈₈, Cys₃₃-Cys₁₃₉) are more stable than the corresponding fusions to normal human EPO or to normal EPO from non-human animals.
- 15 Thus, the invention presents novel forms of EPO and EPO fused to other moieties, preferably an Fc moiety, that have patterns of cysteine residues and disulfide bonds that are different from human and animal EPO. These novel forms of EPO have significant advantages over corresponding natural forms of EPO. For example, forms of EPO with altered disulfide bonding patterns have
- 20 higher specific activity, increased stability, dramatically increased stability in the presence of other alterations that destabilize EPO, and improved pharmacokinetics. Some of the Examples below illustrate these points. For example, enzymatic deglycosylation of EPO has a destabilizing effect on EPO activity. A form of EPO with an altered pattern of disulfide bonds is more stable
- 25 upon deglycosylation than the corresponding form of EPO with the normal disulfide bonding pattern. In addition, a form of EPO with an altered pattern of disulfide bonding has a greater specific activity than the corresponding form of EPO with a normal pattern of disulfides.
- 30 Thus, it is also an object of the present invention to provide a novel recombinant human or animal preferably mammalian (non-Fc-fused) erythropoietin (EPO) having the pattern of disulfide bonds that differs from the disulfide bonding pattern of human or animal / mammalian EPO. Animal or mammalian EPO according to the invention may derive from mice, macaques, rats, dogs, pigs, cows or sheep.

Furthermore, it is an object of the present invention to provide a fusion protein as defined above and in the claims, wherein the EPO or EPO_m portions within the Fc fusion protein are dimerized.

The term "dimeric" refers to a specific multimeric molecule, wherein two protein subunits are stably associated through covalent or non-covalent interactions. As used herein, the term "multimeric" refers to the stable association of two or more protein subunits by means of covalent interaction, for example, by a disulfide bond or by means of non-covalent interaction.

It should be understood that the Fc fragment itself typically is a dimer of the heavy chain fragments including at least a portion of the hinge region, CH₂ domain and CH₃ domain. However, many protein ligands are known to bind to their receptors as a dimer. If a protein ligand X dimerizes naturally, the X moiety in a Fc-X molecule will dimerize to a much greater extent, since the dimerization process is concentration dependent. The physical proximity of the two X moieties connected by Fc would make the dimerization an intramolecular process, greatly shifting the equilibrium in favor of the dimer and enhancing its binding to the receptor.

It is another object according to the invention to construct EPO fusion proteins, wherein a whole or intact Ig molecule is used. Such fusion molecules comprise the variable regions of heavy and light chains of an antibody and the epitopes binding to a specific antigen. For example, erythropoietin is fused to the C-terminus of an antibody heavy chain within an antibody whose variable regions are directed against an antigen to which much or all of the human population has been exposed. Such an antibody is termed a "universal antibody" in this disclosure. It is important to note that the use of "universal" antibodies in the construction of antibody fusion proteins can be generalized to fusion molecule with other protein moieties besides erythropoietin. By a "universal" antibody is meant an antibody with a specificity that is found in much, most, or all of a mammalian population, such as the human population.

For example, variable regions directed against tetanus toxoid are encoded in the human genome and the corresponding proteins are generally represented in the serum without having experienced somatic mutation. Thus, according to the invention, erythropoietin is fused to the C-terminus of a heavy chain of an

antibody directed against tetanus toxoid. An advantage of such an antibody-erythropoietin fusion is that the antibody variable regions do not bind strongly to a mammalian self-antigen. A second advantage is that anti-idiotypic antibodies are less likely to be generated de novo against such an antibody than to an antibody
5 with an uncharacterized variable region.

DNA constructs encoding whole antibody fusion proteins may be constructed as described previously (Gillies et al. [1991] *Hybridoma* 10:347-356).

The invention also relates to a DNA molecule that encodes any of the fusion
10 proteins disclosed above and depicted in the claims.

As a preferred embodiment a DNA molecule is disclosed that encodes a fusion protein as defined above and in the claims comprising:

- (a) a signal / leader sequence
- 15 (b) a Fc region of an Ig molecule
- (c) a target protein sequence having the biological activity of EPO.

The signal sequence of the invention as indicated above is a polynucleotide which encodes an amino acid sequence that initiates transport of a protein across
20 the membrane of the endoplasmic reticulum. Signal sequences which will be useful in the invention include antibody light chain signal sequences, e.g., antibody 14.18 [Gillies et al. (1989) *Jour. of Immunol. Meth.*, 125:19 1], antibody heavy chain signal sequences, e.g., the MOPC141 antibody heavy chain signal sequence [Sakano et al. (1980) *Nature* 286:5774], and any other signal
25 sequences which are known in the art (see for example, Watson, 1984, *Nucleic Acids Research* 12:5145). Each of these references is incorporated herein by reference. Signal sequences have been well characterized in the art and are known typically to contain 16 to 30 amino acid residues, and may contain greater or fewer amino acid residues. A typical signal peptide consists of three regions: a
30 basic N-terminal region, a central hydrophobic region, and a more polar C-terminal region. The central hydrophobic region contains 4 to 12 hydrophobic residues that anchor the signal peptide across the membrane lipid bilayer during transport of the nascent polypeptide. Following initiation, the signal peptide is

usually cleaved within the lumen of the endoplasmic reticulum by cellular enzymes known as signal peptidases.

Potential cleavage sites of the signal peptide generally follow the "(-3, -1) rule".

Thus a typical signal peptide has small, neutral amino acid residues in positions
5 -1 and -3 and lacks proline residues in this region. The signal peptidase will cleave such a signal peptide between the -1 and +1 amino acids. Thus, the portion of the DNA encoding the signal sequence may be cleaved from the amino-terminus of the Fc- fusion protein during secretion. This results in the secretion of a Fc-fusion protein consisting of the Fc region and the target protein.
10 A detailed discussion of signal peptide sequences is provided by von Heijne (1986) Nucleic Acids Res., 14:4683. As would be apparent to one of skill in the art, the suitability of a particular signal sequence for use in a secretion cassette may require some routine experimentation. A signal sequence is also referred to as a "signal peptide", "leader sequence" or "leader peptides" and each of these
15 terms having meanings synonymous to signal sequence may be used herein.

The invention also relates to expression vectors comprising said DNA molecules which promote expression of the target protein, that is a Fc-EPO fusion protein.

As used herein, "vector" means any nucleic acid comprising a nucleotide
20 sequence competent to be incorporated into a host cell and to be recombined with and integrated into the host cell genome, or to replicate autonomously as an episome. Such vectors include linear nucleic acids, plasmids, phagemids, cosmids, RNA vectors, viral vectors and the like. Non-limiting examples of a viral vector include a retrovirus, an adenovirus and an adeno-associated virus.
25 As used herein, "expression of a target protein" is understood to mean the transcription of the DNA sequence, translation of the mRNA transcript, and secretion of a protein product that is folded into a correct, active conformation.

According to the invention eukaryotic, preferably mammalian, host cells are used
30 that are suitable for expressing a fusion protein as defined in this application. Methods of transfecting such host cells with said vector, expressing, purifying and isolating the fusion proteins of this invention are well known in the art.

Therefore, the method according to this invention comprises:

(i) constructing a DNA encoding a precursor protein that comprises from N-

terminus to C-terminus a leader sequence for secretion, the Fc portion and the EPO, EPO_m or EPO_{trunc}.

- (ii) placing said fused DNA in an appropriate expression vector,
- (iii) expressing said fusion protein in a eukaryotic cell, and
- 5 (iv) purifying said secreted fusion protein.

Finally, the invention also relates to pharmaceutical compositions comprising at least one of the EPO forms as defined above and below, preferably a Fc-EPO fusion protein, together with pharmaceutically acceptable carriers, diluents, and
10 excipients. These pharmaceutical compositions may optionally contain other drugs or medicaments that are helpful in co-treating EPO deficient diseases.

Such pharmaceutical compositions may be for parenteral administration, or for oral, pulmonary, nasal, transdermal or other forms of administration. In general, comprehended by the invention are pharmaceutical compositions comprising
15 effective amounts of protein or derivative products of the invention together with pharmaceutically acceptable diluents, preservatives, solubilizers, emulsifiers, adjuvants and/or carriers. Such compositions include diluents of various buffer content (e.g., Tris-HCl, acetate, phosphate), pH and ionic strength; additives such as detergents and solubilizing agents (e.g., Tween 80, Polysorbate 80),
20 anti-oxidants (e.g., ascorbic acid, sodium metabisulfite), preservatives (e.g., Thimersol, benzyl alcohol) and bulking substances (e.g., lactose, mannitol). The term "parenteral" as mentioned above and below includes subcutaneous, intravenous, intra-articular and intratracheal injection and infusion techniques. The parenteral administration is preferred.

25 As used herein, the term "pharmaceutically acceptable carrier or excipient" means an inert, non toxic liquid filler, diluent, solvent or solution, not reacting adversely with the active compounds or with the patient. Suitable liquid carriers are well known in the art such as steril water, saline, aqueous dextrose, sugar solutions, ethanol, glycols and oils, including those of petroleum, animal,
30 vegetable, or synthetic origin. The formulations may also contain adjuvants or vehicles which are typical for parenteral administration.

With respect to said suitable formulations it should be pointed out that the Fusion proteins of the present invention may eventually form pharmaceutically

acceptable salts with any non-toxic, organic or inorganic acid showing changed solubility. Inorganic acids are, for example, hydrochloric, sulphuric or phosphoric acid and acid metal salts such as sodium monohydrogen orthophosphate and potassium hydrogen sulfate. Examples for organic acids are the mono, di and tri
5 carboxylic acids such as acetic, glycolic, lactic, pyruvic, malonic, succinic, glutaric, fumaric, malic, tartaric, citric, ascorbic, maleic, benzoic, phenylacetic, cinnamic, salicylic and sulfonic acids. Salts of the carboxy terminal amino acid moiety include the non-toxic carboxylic acid salts formed with any suitable inorganic or organic bases. These salts include, for example, alkali metals such
10 as sodium and potassium, alkaline earth metals such as calcium and magnesium, and organic primary, secondary and tertiary amines such as trialkylamines.

Preferably, the dosage of the pharmaceutical composition according to the invention will be such that between about 10 ng / kg / day and about 10 µg / kg /
15 day will yield the desired therapeutic effect. The effective dosages may be determined using diagnostic tools which are known in the prior art. In general, the optimum therapeutically acceptable dosage and dose rate for a given patient within the above-said ranges depends on a variety of factors, such as the activity of the specific active material employed, the age, body weight, general health,
20 sex, diet, time and route of administration, rate of clearance or the object of treatment. One skilled in the art will be able to ascertain effective dosages by administration and observing the desired therapeutic effect. The dosages may also vary over the course of therapy, with a relatively high dosage being used initially, until therapeutic benefit is seen, and lower dosages used to maintain the
25 therapeutic benefits.

Short Description of the Figures

Figure 1:

30 Fc-Erythropoietin treated with N-glycosidase
SDS gel showing Fc-erythropoietin before and after N-glycosidase F treatment. Lane 1 shows molecular weight size standards, lane 2 is blank, lane 3 shows normally glycosylated Fc-EPO, lane 4 shows normally glycosylated Fc-EPO after

incubation in deglycosylation buffer, and lanes 5, 6, and 7 respectively show normally glycosylated Fc-EPO incubated with 20 units of N-glycosidase F (Boehringer-Mannheim) in 0.5 mls for 3 hours, 6 hours, or 18 hours.

5 Figure 2:

This figure depicts a line graph showing the biological activity of the NIBSC EPO (black diamonds), human IgG2 Fc-EPO (white squares), human IgG1 Fc-EPO with mutant glycosylation sites (white circles), and human IgG2 Fc-EPO expressed in CHO-Lec2 cells (white diamonds). The activity of the EPO moiety in various proteins was assayed via EPO-dependent 3H-thymidine incorporation into TF-1 cells. The X-axis indicates the EPO equivalents (ng/ml) present as determined by ELISA, and the Y-axis indicates the dependent 3H-thymidine incorporation in counts per minute.

15 Figure 3:

This figure depicts a line graph showing the biological activity of human IgG2 Fc-EPO treated with neuraminidase for various times. Fc-EPO was treated with buffer alone (black circles), 0.1 units of neuraminidase for 15 minutes (white squares), for 1 hour (white diamonds), for 3.5 hours (white triangles), or for 22 hours (white circles). The activity of the EPO moiety in various proteins was assayed via the EPO-dependent 3H-thymidine incorporation into TF-1 cells. The X-axis indicates the EPO equivalents (ng/ml) present, and the Y-axis indicates the dependent 3H-thymidine incorporation in counts per minute.

25 Figure 4:

Figure 4 depicts an HPLC profile of purified Fc-EPO in which the EPO moiety had the human EPO sequence except for the following alterations: His₃₂ → Gly, Cys₃₃ → Pro, Trp₈₈ → Cys, and Pro₉₀ → Ala. The peak at 7.064 represents (Fc-EPO)₂, and the peak at 5.302 represents aggregated material with a molecular weight of at least 800,000 daltons. The peak at 7.064 represents 93.2% of the detected material, while the peak at 5.302 represents 6.8% of the loaded material.

Figure 5:

This figure depicts an HPLC profile of purified Fc-EPO in which the EPO moiety had the human EPO sequence. The peak at 7.254 represents (Fc-EPO)₂, the peak at 6.079 represents an oligomeric aggregate of (Fc-EPO)₂, and the peak at 5.330 represents aggregated material with a molecular weight of at least 800,000 daltons. The peak at 7.254 represents 43.4% of the detected material, while the peaks at 6.079 and at 5.330 respectively represent 30.5% and 25.2% of the loaded material.

10 Sequence Information

The following DNA and amino acid sequences were used in this invention

The coding sequence for mature EPO, using modified codons to optimize translation and including bases at the 5' end comprising the SmaI site is given in

15 Seq. Id. No. 1.

SEQ ID NO:1

(Small characters indicate base differences from the human EPO coding sequence that are predicted to increase expression but not change protein sequence.)

20 CCCGGGIGCCCCACCACGCCTCATCTGTGACAGCCGAGTgCTGGAGAGGTACCTCT
TGGAGGCCAAGGAGGCCGAGAATATCACGACcGGCTGTGCTGAACACTGCAGCTT
GAATGAGAAcATCACcGTgCCIGACACCAAAGTgAATTTCTATGCCTGGAAGAGGATG
GAGGTIGGcCAGCAGGCCGTAGAAGTgTGGCAGGGCCTGGCCCTGCTGTGCGAAG
CTGTCCTGCGGGGCCAGGCCCTGTTGGTCAACTCTTCCCAGCCGTGGGAGCCCCCT
25 GCAaCTGCATGTGGATAAAGCCGTgAGTGGCCTTCGCAGCCTCACCCTCTGCTTC
GGGCTCTGgGAGCCCAGAAGGAAGCCATCTCCCCTCCAGATGCGGCCTCAGCTGC
TCCcCTCCGcACAATCACTGCTGACACTTTCCGCAAACCTTCCGAGTCTACTCCAAT
TTCCTCCGGGAAAGCTGAAGCTGTACACAGGGGAGGCCTgcCGGACAGGGGACA
GATGActcgag

30

SEQ ID NO:2

The mature EPO protein sequence (one-letter code)

APPRLICDSRVLERYLLEAKEAENITTGCAEHCSLNENITVPDTKVNIFYAWKRMEVGQQ
AVEVWQGLALLSEAVLRGQALLVNSSQPWEPLQLHVDKAVSGLRSLTLLRALGAQKE
AISPPDAASAAPLRITADTFRKLFRVYSNFLRGKLKLYTGEACRTGDR

35

Oligonucleotides used to construct a fusion of normally glycosylated EPO to the C-terminus of an Fc region.

SEQ ID 3: Oligo 1

CCGGGIGCCCCACCACGCCTCATCTGTGACAGCCGAGTgCTGGAGAGGTACC

5 SEQ ID 4: Oligo 2

TCTTGAGGCCAAGGAGGCCGAGAATATCACGACcGGCTGTGCTGAACA

SEQ ID 5: Oligo 3

CTGCAGCTTGAATGAGAAcATCACcGTgCCIGACACCAAAGTgAATTTCTAT

SEQ ID 6: Oligo 4

10 GCCTGGAAGAGGATGGAGGTtGGcCAGCAGGCCGTAGAAGTgTGGCAG

SEQ ID 7: Oligo 5

GGCCTGGCCCTGCTGTCTGGAAGCTGTCTGCGGGGCCAGGCCCTGTTGGTC

SEQ ID 8: Oligo 6

AACTCTTCCCAGCCGTGGGAGCCCCTGCAaCTGCATGTGGATAAAGCCG

15 SEQ ID 9: Oligo 7

TgAGTGGCCTTCGCAGCCTCACCCTCTGCTTCGGGCTCTGgGAGCCCAGAA

SEQ ID 10: Oligo 8

GGAAGCCATCTCCCCTCCAGATGCGGCCTCAGCTGCTCCcCTCCGcAC

SEQ ID 11: Oligo 9

20 AATCACTGCTGACACTTTCCGCAAACCTTCCGAGTCTACTCCAATTTCTCC

SEQ ID 12: Oligo 10

GGGAAAGCTGAAGCTGTACACAGGGGAGGCCTgcCGGACAGGGGACAGATGActc
gag

25 Mutagenesis of glycosylation sites:

SEQ ID 13: Oligo 11 (oligo 2')

tc ttgaggcca aggaggccga gcagatcacg acgggctgtg ctgaaca

TCTTGAGGCCAAGGAGGCCGAGCAGATCACGACcGGCTGTGCTGAACA

SEQ ID 14: Oligo 12 (oligo 3')

30 CTGCAGCTTGAATGAGCAGATCACcGTgCCIGACACCAAAGTgAATTTCTAT

SEQ ID 15: Oligo 13 (oligo 6')

CAGTCTTCCCAGCCGTGGGAGCCCCTGCAaCTGCATGTGGATAAAGCCG

SEQ ID 16: Oligo 14 (oligo 8')

GGAAGCCATCTCCCCTCCAGATGCGGCCGCAGCTGCTCCcCTCCGcAC

SEQ ID 17:*Human IgG1 Fc region – mature protein coding sequence*

EPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVK
 FNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPI
 5 EKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN
 YKTTTPVLDSGDSFFLYSKLTVDKSRWQQGNVFSVSMHEALHNHYTQKSLSLSPGK

SEQ ID 18:*Human IgG2 constant region – mature protein coding sequence (CH1, hinge,*10 *CH2, and CH3 regions)*

ASTKGPSVFP LAPCSRSTSE STAALGCLVK DYFPEPVTVS WNSGALTSGV
 HTFPAVLQSSGLYSLSSVVT VPSSNFGTQT YTCNVDHKPS NTKVDKTVR
 KCCVECPPCP APPVAGPSVFLFPPKPKDTL MISRTPEVTC VVVDVSHEDP
 EVQFNWYVDG VEVHNAKTKP REEQFNSTFRVSVLTVVHQ DWLNGKEYKC
 15 KVSNGKLPAP IEKTISKTKG QPREPQVYTL PPSREEMTKNQVSLTCLVKG
 FYPSDIAVEW ESNGQPENNY KTTTPMLDSD GSFFLYSKLT VDKSRWQQGN
 VFSCSVSMHEA LHNHYTQKSL SLSPGK

The following examples describe the invention in more detail without limiting it.

20

Example 1.Expression of human Fc-EPO

A sequence encoding the mature form of erythropoietin was completely
 synthesized from oligonucleotides by standard techniques. The oligonucleotides
 25 shown above and in the Sequence Listing indicate the 'top' strand of DNA
 encoding EPO protein; 'bottom' strand oligonucleotides were designed to pair
 with the top strands and to generate 4 to 5 base protruding 5' ends so that the
 entire EPO coding sequence could be ligated together after phosphorylation of
 the oligonucleotides. The sequence was designed to have a high G/C content
 30 with optimal codon usage for high-level expression.

The protein according to SEQ ID 2 does not have the N-terminal lysine residue of
 the mature protein. The synthesized DNA was engineered to have an XmaI-
 compatible overhang at the 5' end and an XhoI-compatible overhang at the 3'
 35 end. An alternative sequence was constructed with mutations in the four EPO

glycosylation sites: Asn₂₄ → Gln, Asn₃₈ → Gln, Asn₈₃ → Gln, and Ser₁₂₆ → Ala.

The 500 base-pair DNA was cloned and sequence analysis confirmed that it encodes the mature human EPO without additional undesired mutations.

The expression vector pdCs-Fc-EPO was constructed as follows. The XmaI-XhoI
5 restriction fragment containing the human EPO cDNA was ligated to the XmaI-XhoI fragment of the pdCs-Fc vector according to Lo *et al.* [Protein Engineering (1998) 11:495]. The resultant vector, pdCs-Fc-EPO, was used to transfect mammalian cells for the expression of Fc-EPO. This vector expresses the human immunoglobulin gamma1 chain Fc region. A second set of Fc-EPO vectors were
10 constructed in which the gamma1 chain Fc region was replaced with an Fc region derived from human gamma2.

The Fc protein moiety also usually contains a glycosylation site. This site may be optionally changed to a non-glycosylated sequence by standard approaches.

15 Example 2.

Transfection and expression of Fc-EPO fusion proteins

For transient transfection, the plasmids were introduced into BHK cells. Cells were transfected by coprecipitation of plasmid DNA with calcium phosphate [Sambrook *et al.* (1989) Molecular Cloning—A Laboratory Manual, Cold Spring
20 Harbor, NY] or by lipofection using Lipofectamine Plus (Life Technologies, Gaithersburg, MD) according to supplier's protocol.

To generate stable cell lines, NS/O cells were used for both transient transfection and the generation of stable cell lines. To express proteins lacking the normal sialic acid modification, CHO-Lec2 cells (ATCC Number: CRL-1736) This cells
25 exhibit a drastic reduction in the transport of CMP-sialic acid into the Golgi compartment, and are useful for studying the contribution of sialic acid in protein function.

In order to obtain stably transfected clones, plasmid DNA was introduced into cells by electroporation. About 5×10^6 cells were washed once with PBS and
30 resuspended in 0.5 ml PBS. Ten µg of linearized plasmid DNA were then incubated with the cells in a Gene Pulser Cuvette (0.4 cm electrode gap, BioRad) on ice for 10 min. Electroporation was performed using a Gene Pulser (BioRad, Hercules, CA) with settings at 0.25 V and 500 microF. Cells were allowed to

recover for 10 min. on ice, after which they were resuspended in growth medium and then plated onto two 96 well plates. Stably transfected clones were selected by growth in the presence of 100 nM methotrexate (MTX), which was introduced two days post-transfection. The cells were fed every 3 days for two to three more
5 times, and MTX-resistant clones appeared in 2 to 3 weeks. Supernatants from clones were assayed by anti-Fc ELISA to identify high producers. High producing clones were isolated and propagated in growth medium containing 100 nM MTX.

BHK cells and NS/O cells were grown in Dulbecco's modified Eagle's medium
10 supplemented with 10% fetal bovine serum, 2 mM glutamine and penicillin/streptomycin. CHO-Lec2 cells were grown in alpha medium supplemented with 10% fetal bovine serum and penicillin/streptomycin. For routine characterization by gel electrophoresis, Fc fusion proteins in the conditioned media were captured on Protein A Sepharose (Repligen, Cambridge,
15 MA) and then eluted by boiling in the protein sample buffer with or without 2-mercaptoethanol. After electrophoresis on an SDS gel, the protein bands were visualized by Coomassie staining. Fc-EPO had an apparent MW of about 64 kD on SDS-PAGE.

For purification, the fusion proteins bound on Protein A Sepharose were eluted in
20 a sodium phosphate buffer (100 mM NaH₂PO₄, pH 3, and 150 mM NaCl). The eluate was then immediately neutralized with 0.1 volume of 2 M Tris-hydrochloride, pH 8.

Example 3.

25 Synthesis of desialylated and deglycosylated EPO and Fc-EPO protein by enzyme treatment

Sialic acid residues were removed from EPO and Fc-EPO by treatment with neuraminidase. Fc-erythropoietin protein at 500 micrograms/ml was treated with 0.1 units/ml of enzyme (Roche Biologicals) in a buffer containing 50 mM sodium
30 acetate, 4 mM calcium chloride, 100 micrograms/ml bovine serum albumin at pH 5.5 for various times at 37°C.

Data in Figure 2 illustrate that human IgG2 Fc-EPO treated with neuraminidase has an increased activity. For example, Fc-EPO that has been treated with

neuraminidase for 22 hours has an activity equal to that of about 2 to 5 times as much normally sialylated Fc-EPO control protein.

To completely remove the N-linked sugar moieties, N-glycosidase treatment was used. Fc-erythropoietin protein at 500 micrograms/ml was treated with 0.02
5 units/ml of enzyme (Roche Biologicals) in a buffer containing 50 mM phosphate pH 7.8 for various times at 37°C. Alternatively, a buffer containing 50 mM phosphate pH 7.8, 20 mM EDTA, 1% Triton X-100, 1% beta-mercaptoethanol, and 0.1% SDS is used.

10 **Example 4.**

Characterization of Fc-EPO and deglycosylated Fc-EPO

To characterize the deglycosylated forms of Fc-EPO that were generated by enzyme treatment or expression in mutant cell lines, SDS-PAGE and isoelectric focusing experiments were carried out. As determined by SDS-PAGE, the Fc-
15 EPO protein that was deglycosylated by N-glycosidase treatment showed significantly faster mobility (Figure 1).

The Fc-EPO protein is a dimer with four N-glycosylation sites and one O-glycosylation site in each subunit, for a total of ten glycosylation sites and 36 sialic acid residues. Each one of these sites is incompletely modified, so that Fc-

20 **EPO has many forms when analysed by IEF.**

When Fc-EPO is treated with neuraminidase, certain IEF bands disappear and others appear, consistent with the removal of sialic acid by this enzyme.

Similarly, Fc-EPO that is produced by from CHO-lec2 cells has a smaller number of less acidic forms.

25

Example 5.

ELISA procedures

ELISAs were used to determine the concentrations of protein products in the supernatants of MTX-resistant clones and other test samples. The amounts of
30 human Fc- and murine Fc-containing proteins were determined by the anti-huFc ELISA and the anti-muFc ELISA, respectively.

ELISA plates were coated with AffiniPure Goat anti-Human IgG (H+L) (Jackson Immuno Research Laboratories, West Grove, PA) at 5 µg/mL in PBS, and 100 µl/well in 96-well plates (Nunc-Immuno plate Maxisorp). Coated plates were

covered and incubated at 4°C overnight. Plates were then washed 4 times with 0.05% Tween (Tween 20) in PBS, and blocked with 1% BSA/1% goat serum in PBS, 200 µl/well. After incubation with the blocking buffer at 37°C for 2 hrs, the plates were washed 4 times with 0.05% Tween in PBS and tapped dry on paper
5 towels.

Coated plates were incubated with test samples diluted to the proper concentrations. Sample buffer contains 1% BSA, 1% goat serum and 0.05% Tween in PBS. A standard curve was prepared with a chimeric antibody (with a human Fc), the concentration of which was known. To prepare a standard curve,
10 serial dilutions are made in the sample buffer to give a standard curve ranging from 125 ng/mL to 3.9 ng/mL. The diluted samples and standards were added to the plate, 100 µl /well and the plate was incubated at 37°C for 2 hr. After incubation, the plate was washed 8 times with 0.05% Tween in PBS. To each well was then added 100 µl of the secondary antibody, the horseradish

15 peroxidase-conjugated anti-human IgG (Jackson Immuno Research), diluted according to manufacturers instruction in the sample buffer. After incubation at 37°C for 2 hr, the plate was washed 8 times with 0.05% Tween in PBS.

Substrate solution have been added to the plate at 100 µl/well. The substrate solution was prepared by dissolving 30 mg of OPD (o-phenylenediamine
20 dihydrochloride, 1 tablet) into 15 mL of 0.025 M Citric acid/0.05 M Na₂HPO₄ buffer, pH 5, which contained 0.03% of freshly added H₂O₂. The color was allowed to develop for 30 min. at room temperature in the dark. The developing time is subject to change, depending on lot to lot variability of the coated plates, the secondary antibody, etc. Watch the color development in the standard curve
25 to determine when to stop the reaction. The reaction was stopped by adding 4N H₂SO₄, 100 µl/well. The plate was read by a plate reader, which was set at both 490 and 650 nm and programmed to subtract the background OD at 650 nm from the OD at 490 nm.

The procedure for the anti-muFc ELISA is similar, except that ELISA plate was
30 coated with AffiniPure Goat anti-murine IgG (H+L) (Jackson Immuno Research) at 5 µg/mL in PBS, and 100 µl/well; and the secondary antibody was horseradish peroxidase-conjugated goat anti-mulgG (Southern Biotechnology Assoc., Birmingham, AL).

Example 6:In vitro activity of human Fc-EPO fusion proteins

The methods below were and are used to test the activity of human Fc-EPO proteins produced by transient and stable expression. The amount of each fusion protein in the cell culture supernatant was first determined by ELISA and used to set up a dose-response curve. The activities closely corresponded to what was found with the Fc-EPO fusion proteins and described above.

Specifically, the EPO activity of a human Fc-EPO and asialo- human Fc-EPO molecules were tested in the TF-1 cell proliferation assay, following a standard procedure known to those practiced in the art of molecular immunology (Hammerling et al. [1996] J. Pharmaceutical and Biomedical Analysis 14:1455-1469; Kitamura et al. [1989] J. Cellular Physiol. 140:323-334). The human TF-1 cell line proliferates in response to EPO or other cytokines and growth factors. TF-1 cells in active log-phase growth were washed twice in medium lacking EPO and plated at about 1×10^4 cells per well in microtiter wells in the presence of various amounts of commercial EPO or Fc-EPO fusion protein with or without sialic acids. Cells were incubated in the presence of various test proteins for 48 hours, and 0.3 microCuries of ^3H -thymidine was added ten hours before determining levels of radioactive incorporation. The various EPO and Fc-EPO fusion proteins stimulated incorporation of ^3H -thymidine into cells in a dose-dependent manner, and were about equally effective in stimulating incorporation of ^3H -thymidine on a per mole basis.

These results indicated that the *in vitro* biological activity of Fc-EPO increased upon desialylation by neuraminidase. The results also indicate that Fc-EPO fusion proteins, with or without sialylation, had activity similar to human EPO. Specifically, Figure 1 indicates that the biological activity of normally sialylated human IgG2 Fc-EPO was about 2 to 5-fold less than that of enzymatically desialylated human IgG2 Fc-EPO, and the activities of these Fc-EPO fusion proteins were similar to the NIBSC EPO on a per mole basis.

Example 7Site-directed mutagenesis of unglycosylated EPO

Mutations that increase the activity of unglycosylated EPO are introduced into the Fc-unglycosylated EPO fusion protein as follows. A DNA sequence encoding unglycosylated EPO is constructed as described in Example 1, except that one

pair of oligonucleotides is replaced with a corresponding pair of oligonucleotides encoding a portion of EPO with one or more altered amino acids. For example, to introduce the change Asn₁₄₇Ala, the oligonucleotide

AATCACTGCTGACACTTCCGCAAACCTCTCCGAGTCTACTCCGCATTCCTCC

5 is used instead of oligo 9 (SEQ ID 11), along with a correspondingly altered reverse-complement oligonucleotide.

The following mutations are introduced by this procedure: Gly₁₀₁Ala, Arg₁₄₃Ala, Ser₁₄₆Ala, and Asn₁₄₇Ala. These mutations most likely have the effect of increasing the activity of Fc-EPO by increasing its affinity for the EPO receptor.

10 As another example, Gln₆₅ is mutated to an amino acid that has a smaller and/or more hydrophobic side chain. The effect of this mutation is to increase the fraction of Fc-EPO that is active. This effect is pronounced when mutations in the region of amino acids 114 to 130 are also present.

In other versions, cysteine residues are inserted and removed by substitution as
15 described in Example 13. The resulting protein is more stable and more efficiently expressed, especially when combined with the mutations described above..

Example 8:

20 Testing site-directed mutants for activity

To rapidly test the mutant forms of Fc-unglycosylated EPO, the following strategy was used. A plasmid encoding each mutant form is transfected into mammalian cells, such as BHK cells. Tissue culture supernatant was withdrawn and quantitated by ELISA for human Fc, human EPO, and for activity in the TF1 cell
25 proliferation assay. Four dilutions of each supernatant was tested in duplicate. The Fc-unglycosylated EPO concentrations in the dilutions was about 0.01 nM, 0.1 nM, 1 nM, and 10 nM.

Example 9:

30 Random mutagenesis of Fc-EPO

To generate mutant forms of Fc-unglycosylated EPO without pre-selection, one of the following procedures is used. For example, the mature unglycosylated EPO coding sequence is synthesized as described in Example 1, except that 10 separate pools are generated. In the first pool. Oligo 1 and its reverse

complement are synthesized with mixtures of oligonucleotide precursors so that each nucleotide has a 3% chance of being mutant. As a result, on average, each oligonucleotide will have 1 to 2 amino acid substitutions. Similarly, in the second pool, Oligo 2 and its reverse complement are synthesized with mixtures of
5 oligonucleotide precursors so that each nucleotide has a 3% chance of being mutant, and so on.

After ligation and transformation into *E. coli*, about 20 colonies are picked for each pool. DNA is made from each of the 20 transformants, and then separately introduced into a mammalian cell line such as BHK cells. Supernatant from each
10 set of transiently transfected cells is then tested for EPO activity as described in Example 9.

Particular transfected BHK lines are found to produce EPO with greater specific activity. The corresponding DNA sequences of the mutant coding regions are determined. Based on these mutations and mutations identified in the Examples
15 above, multiply mutant coding sequences are constructed. The corresponding multiply mutant proteins are expressed, and certain forms are found to have specific activities that are even greater than the individually mutant "parental" forms.

20 **Example 10**

Pharmacokinetic data

At present, erythropoietin is normally administered to patients three times per week (Physicians' Desk Reference [1996] "EPOgen: EPOetin Alfa", p. 489-496). The serum half-life of intravenously administered erythropoietin is about 4 to 13
25 hours. After subcutaneous administration of erythropoietin, serum levels peak within 5 to 24 hours. It would be advantageous to have a protein that stimulates red blood cell production but with a longer serum half-life than erythropoietin, so that dosing could be less frequent.

Example 11

30 Pharmacokinetics of Fc-EPO fusion proteins

The human EPO protein and certain human Fc-EPO fusion proteins were tested for their pharmacokinetic behavior following intravenous injection into Balb/c mice. Blood was collected from mice by retro-orbital bleeding and stored at 4°C in Eppendorf micro-centrifuge tubes. ELISA methods were used to measure the

amount of human antibody-related proteins, such as the human Fc region, remaining in the blood at various time points. The ELISA measuring human antibody used an antibody against human H and L chains for capture and an anti-human Fc antibody for detection. A Western blot was used to verify that the Fc-erythropoietin fusion protein retained the correct size and was not degraded.

As an alternative method to detect intact Fc-erythropoietin fusion protein moieties, a modified ELISA method was used. This fusion protein-specific assay uses the same first capture step, but an anti-human EPO antibody for detection. To detect EPO alone, both the capture antibody and the detection antibody are specific for human EPO. For example, the human EPO detection kit is used.

The Fc-EPO fusion had a serum half-life of about 2 to 4 hours in these experiments. In contrast, the serum half-life of certain more elaborately engineered Fc-EPO fusions is tested and found to be much longer. For example, an intact antibody-EPO fusion is tested and has a serum half-life in mice of about 10 to 20 hours or longer.

The serum half-life of intact asialo-EPO was determined to be very short. As determined by Western blotting using antibodies against human IgG as a probe, the erythropoietin moiety of the asialo-Fc-EPO fusion protein is rapidly degraded while the Fc moiety is relatively stable and retained in the serum. These results indicate that only certain Fc-EPO fusion proteins have long serum half-lives, and that the Fc moiety is not universally sufficient to extend the serum half-life of a protein.

Example 12

In vivo activity of Fc-EPO fusion proteins

The *in vivo* activity of the human Fc-EPO fusion protein was tested and compared with that of intact human EPO. On a per mole basis, the activity of Fc-erythropoietin is similar to that of intact human EPO using an assay that measures stimulation of red blood cell production within a short period after administration.

The activity of human EPO and IgG2 Fc-EPO was assayed in the normocythaemic mouse assay. One week before the beginning of the assay procedure, 8-week old male mice of the strain B6D2F1 were distributed into cages with six animals per cage. Within each cage group, each animal was

injected with 0.5 mls of 10, 20 or 40 micrograms/ml of either erythropoietin or Fc-EPO, where the dose of Fc-EPO was measured by calculation of the amount of EPO monomers as determined by ELISA. For each experiment, 8 animals were used for each dose group.

- 5 Four days after the injections, blood samples were collected and the number of reticulocytes per 30,000 red blood cells was determined as follows. One microliter of whole blood was added to 1 milliliter of 0.15 micromolar acridine orange. After staining for 3 to 10 minutes, the reticulocyte count was determined microfluorometrically in a flow cytometer, by analysis of the red fluorescence
- 10 histogram. The following data was obtained:

Table: 1

Number of reticulocytes per 30,000 red blood cells

	EPO			IgG2 Fc-EPO		
	10	20	40	10	20	40
Average	1177	1422	1820	1036	1322	1732
Standard deviation	119	102	197	75	83	178

- 15 In a variation of this assay, mice are dosed with erythropoietin, Fc-Erythropoietin, Ig-Erythropoietin, and various other forms of Fc-EPO containing mutations, truncations, or altered glycosylation patterns. Reticulocytes are measured as described above, except that blood is sampled at 4 days, 5 days, 6 days, and 7
- 20 days following the injection of the test protein. Performing the experiment in this manner gives an indication of the functional pharmacokinetics of the test protein. It is found that certain forms of Fc-EPO, such as intact Ig-EPO, show functional activity over a longer period of time than normal EPO.

As an alternative method for measuring EPO activity, the *in vivo* activity of human EPO and Fc-EPO proteins is tested by the starved rat assay (Goldwasser E. and

- 25 Gross M. Erythropoietin: assay and study of its mode of action. Methods Enzymol. [1975] 37 Pt B:109-21). Male Sprague-Dawley rats weighing about 215 to 250 grams (about 9 weeks old) are deprived of food on day 1. They are

then injected i.v. with 2 mls of test material on days 2 and 3. The rats are divided into groups of five rats each. To generate a standard curve, one group is injected with physiological saline, and four other groups are injected with 1.0, 1.5, 2.0, or 3.0 Units of erythropoietin per rat, where 1.246 Units corresponds to 1 nanogram of glycoprotein (=26.7 femtomoles; check this). On day four, 28 hours after the second injection, the rats are injected i.p. with 1.0 microCuries of $^{59}\text{Fe}^{3+}$, in physiological saline buffered with citrate. Sixteen to eighteen hours after the $^{59}\text{Fe}^{3+}$ injection, the rats are anaesthetized and bled by cardiac puncture, using heparinized syringes. One ml of blood is withdrawn for counting the radiolabel, and a microhematocrit tube is also filled with blood. The animal is weighed. The per cent of the injected $^{59}\text{Fe}^{3+}$ incorporated into the total red cell mass is calculated, assuming that the blood constitutes 5% of the weight of the animal. The hematocrits are recorded, and data from rats with hematocrits of less than 50 are discarded. The data are evaluated by subtracting the mean of the saline control group from the mean of each test group to obtain the per cent incorporation that is stimulated by EPO or Fc-EPO fusion proteins.

As another alternative, the *in vivo* activity of human EPO and Fc-EPO proteins is tested by the plethoric mouse assay (Goldwasser E. and Gross M. *ibid*). In this assay, mice are given a surplus of red blood cells so that erythropoiesis is suppressed. Methods of creating the plethora of red blood cells include exposure to low pressure (about 0.5 atmospheres), exposure to low oxygen at normal pressure, exposure to a low level of carbon monoxide, or exposure to a gradually decreasing O_2 partial pressure. The mice may be injected s.c. with 2.5 mg of iron-dextran before exposing them to the hypoxic stress, in order to insure that the mice have enough iron for the increased hemoglobin synthesis. Mice are returned to a normal oxygen environment on day 1 and injected with $^{59}\text{Fe}^{3+}$ on day 8.

Alternatively, mouse red cells are injected into the mice. For example, 1 ml of packed, washed isologous red blood cells is injected i.p. on days 1 and 3. Test samples include a saline control and standard doses of 0.05, 0.10 and 0.20 Units per mouse. These are injected on days 5 and 6, and $^{59}\text{Fe}^{3+}$ is injected on day 7, and the mice are bled on day 10. One ml of blood is counted. Some blood is used for a hematocrit. The mice are weighed. The per cent of body weight

represented by blood is assumed to be 8%. If a hematocrit is below 55, data for that mouse are not used.

Variations on these procedures, as well as other procedures, can also be used to determine the *in vivo* activity of various forms of the EPO protein.

5

Example 13.

Construction and expression of Fc-EPO variants containing altered patterns of disulfide bonding.

Mutations that alter the disulfide bonding pattern of the EPO moiety within Fc-

- 10 EPO were introduced as follows. The alterations His₃₂Gly, Cys₃₃Pro, Trp₈₈Cys, and Pro₉₀Ala were introduced into human Fc-EPO by standard site-directed mutagenesis techniques. This protein was termed Fc-EPO (Cys₂₉-Cys₈₈). Fc-EPO (Cys₂₉-Cys₈₈) was expressed in mammalian cells by procedures analogous to those described in the preceding examples. Fc-EPO and Fc-EPO (Cys₂₉-
15 Cys₈₈) protein were purified using a Staph A protein column as described in Example 2.

- Fc-EPO (Cys₂₉-Cys₈₈) was found to be 1.5- to 2-fold more active than Fc-EPO in cell-based assays that measured proliferation of TF-1 cells. To investigate why
20 Fc-EPO (Cys₂₉-Cys₈₈) was more active than Fc-EPO, each purified protein was examined by HPLC. Figures 4 and 5 show typical results. About 1/3 to 1/2 of the Fc-EPO protein migrated through the column with an apparent molecular weight of about 100,000 Daltons, which is the predicted molecular weight of dimeric Fc-EPO, but the remaining 1/2 to 2/3 of the Fc-EPO protein migrated with a much
25 higher molecular weight, indicating that the Fc-EPO was in an aggregated state (for example, as in Figure 4). SDS-PAGE, performed under denaturing and reducing conditions, indicated that this high-molecular weight material was not due to contamination with other proteins. In contrast, about 95% of the Fc-EPO (Cys₂₉-Cys₈₈) protein migrated through the HPLC column with an apparent
30 molecular weight of 100,000 Daltons, and only about 5% of the Fc-EPO (Cys₂₉-Cys₈₈) was in an apparently aggregated state (for example, Figure 5). Standard HPLC conditions were used.

To further investigate the enhanced stability of Fc-EPO (Cys₂₉-Cys₈₈), both Fc-EPO and Fc-EPO (Cys₂₉-Cys₈₈) were treated with N-glycanase, which removes the three N-linked oligosaccharides from erythropoietin. Standard digestion conditions were used in accordance with the manufacturer's instructions. Under these conditions, the N-linked oligosaccharides were completely removed from Fc-EPO and Fc-EPO (Cys₂₉-Cys₈₈) within 1 hour, as determined by SDS-PAGE – incubation longer than 1 hour had no effect on the migration of the Fc-EPO proteins, but it was found that further incubation under conditions of digestion with N-glycanase did cause Fc-EPO. However, not Fc-EPO (Cys₂₉-Cys₈₈), to rapidly lose biological activity, as described below.

After incubation of Fc-EPO or Fc-EPO (Cys₂₉-Cys₈₈) in the presence of N-glycanase for various times, the reaction was terminated by freezing at -20°C and TF-1 cells were incubated with various dilutions of treated Fc-EPOs. Stimulation of ³H-thymidine incorporation was measured and compared with the NIBSC Erythropoietin standard. Results were obtained as shown in the table below.

Table II. *Effect on biological activity of digestion of Fc-EPO and Fc-EPO (Cys₂₉-Cys₈₈) with N-glycanase.*

Treatment	Specific Activity (International units per mg of EPO moiety within a fusion protein)	
	Fc-EPO	Fc-EPO (Cys ₂₉ -Cys ₈₈)
None	55,000	82,000
N-glycanase treatment (0 min)	55,000	89,000
N-glycanase treatment (15 min)	34,000	82,000
N-glycanase treatment (60 min)	3,290	67,000
N-glycanase treatment (120 min)	1,066	67,000

These results indicated that Fc-EPO (Cys₂₉-Cys₈₈) was much more stable upon N-glycanase treatment than Fc-EPO. Without wishing to be bound by theory, it may be that the N-glycanase buffer conditions, namely phosphate-buffered saline, are destabilizing to the deglycosylated EPO moiety within Fc-EPO, or that the N-glycanase is contaminated with proteases that inactivate the EPO moiety.

Introduction of the mutations in Fc-EPO (Cys₂₉-Cys₈₈) allows the formation of a disulfide bond between Cys₂₉ and Cys₈₈ of EPO. Similarly, introduction of analogous mutations into intact, unfused human EPO causes the formation of a disulfide bond between Cys₂₉ and Cys₈₈. The disulfide bond is identified by
5 cleavage with a site-specific endoprotease such as trypsin under non-reducing conditions, followed by analysis of resulting peptides using mass spectrometry or HPLC analysis.

For example, the following set of experiments with controls is performed. Human
10 Fc-EPO, human Fc-EPO (Cys₂₉-Cys₈₈), human EPO, and human EPO (Cys₂₉-Cys₈₈) are cleaved with trypsin in both reducing and non-reducing conditions. These eight samples are analyzed by mass spectrometry. Trypsinized non-reduced human Fc-EPO (Cys₂₉-Cys₈₈) and human EPO (Cys₂₉-Cys₈₈) each give a peak with a high molecular weight, corresponding to
15 EAENITTGCAEGPSLNENITVPDTK + GQALLVNSSQPCEPLQLHVDK with two N-linked glycosylations. Because of its large size and heterogeneity due to the presence of two N-glycosylations, this peak is easily distinguished from the other peaks. This peak is not found in reduced samples or in samples derived from non-mutant human EPO or non-mutant human Fc-EPO. As a further diagnostic test, samples
20 are incubated with N-glycanase before treatment with trypsin. In the samples treated with N-glycanase, the peak corresponding to EAENITTGCAEGPSLNENITVPDTK (pos. 21 – 45, Seq. Id. No. 2) + GQALLVNSSQPCEPLQLHVDK (pos. 77 – 97, Seq. Id. No. 2) is shifted to the size predicted by the molecular weights of the amino acids alone.

25

The Fc-EPO (Cys₂₉-Cys₈₈) is tested further and found to be advantageous in other ways. For example, Fc-EPO (Cys₂₉-Cys₈₈) has superior pharmacokinetic properties when tested in mice, humans, or other mammals. Lyophilized forms of Fc-EPO (Cys₂₉-Cys₈₈) and EPO (Cys₂₉-Cys₈₈) are more stable than the
30 corresponding Fc-EPO and EPO proteins. In long-term stability studies, such as studies of remaining biological activity after extended incubation at elevated temperatures, Fc-EPO (Cys₂₉-Cys₈₈) and EPO (Cys₂₉-Cys₈₈) are more stable than the corresponding Fc-EPO and EPO proteins. Fc-EPO (Cys₂₉-Cys₈₈) and

EPO (Cys₂₉-Cys₈₈) are more resistant to proteases than the corresponding Fc-EPO and EPO proteins.

In addition, it is sometimes useful to introduce mutations into the EPO moiety that are advantageous in certain aspects but that also decrease the stability of the EPO moiety. In such cases, it is useful to also introduce one or more mutations that cause the formation of a disulfide bond between Cys₂₉ and Cys₈₈. The effect of the additional disulfide bond is to enhance the stability of the mutated EPO. For example, mutation of Gly₁₀₁ → Ala, Arg₁₄₃ → Ala, Ser₁₄₆ → Ala, and Asn₁₄₇ → Ala increases the signaling activity of EPO. Mutations of this type have advantages with regard to certain properties of EPO, but destabilize the protein for purposes of pharmaceutical development.

The advantageous properties of a mutation or mutations that cause the formation of a disulfide bond between Cys₂₉ and Cys₈₈ in EPO are also observed in intact EPO without an attached Fc moiety, and also in other forms of EPO such as fusion proteins of EPO to other moieties, forms of EPO that have reduced, increased, or qualitatively altered glycosylation levels, and so on.

In a similar set of experiments, an expression plasmid encoding human Fc-EPO protein containing the mutations Arg₁₃₉ → Cys and Cys₂₉ to another amino acid such as Ala, Val, Leu, or Ile is constructed analogously to the construction of Fc-EPO (Cys₂₉-Cys₈₈). Analysis by protease treatment and mass-spectrometry indicates that this protein contains a disulfide bond between Cys₃₃ and Cys₁₃₉ and is therefore termed Fc-EPO (Cys₃₃-Cys₁₃₉). An analogous expression plasmid encoding human EPO containing the mutations Arg₁₃₉ → Cys and Cys₂₉ to another amino acid such as Ala, Val, Leu, or Ile is also constructed. Fc-EPO (Cys₃₃-Cys₁₃₉) has a number of advantageous properties. For example, Fc-EPO (Cys₃₃-Cys₁₃₉) is primarily in the normal, dimeric form and is less aggregated than human Fc-EPO. For example, when purified Fc-EPO (Cys₃₃-Cys₁₃₉) is analyzed by HPLC, most of the material migrates with an apparent molecular weight of about 100 kD. Another advantageous property is that Fc-EPO (Cys₃₃-Cys₁₃₉) is more active than human Fc-EPO. Without wishing to be

bound by theory, it is most likely that the 100 kD form of both Fc-EPO (Cys₃₃-Cys₁₃₉) and human Fc-EPO is the active form, and the forms with a high apparent molecular weight, as determined by HPLC, have little or no activity. Even though the Fc-EPO (Cys₃₃-Cys₁₃₉) and Fc-EPO (Cys₂₉-Cys₈₈) have increases in activity
5 of 25% to 100%, this improved activity is economically significant because these proteins are expensive to make and large quantities are used to treat the large population of patients who are anemic.

Fc-EPO (Cys₃₃-Cys₁₃₉) also shows improved pharmacokinetics compared to
10 human Fc-EPO. Fc-EPO (Cys₃₃-Cys₁₃₉) also shows improved long-term stability in solution and in a lyophilized form as compared to human Fc-EPO.

Fc-EPO (Cys₃₃-Cys₁₃₉) also has the advantageous property that, in the presence of additional alterations or mutations that destabilize human Fc-EPO, the protein
15 has significantly enhanced stability.

The advantageous properties of Fc-EPO (Cys₃₃-Cys₁₃₉) are also observed with EPO (Cys₃₃-Cys₁₃₉) without the Fc moiety. For example, EPO (Cys₃₃-Cys₁₃₉) has enhanced stability, improved activity, superior pharmacokinetics, improved long-
20 term stability, and significantly enhanced stability in the presence of additional destabilizing alterations.

Other useful forms of human Fc-EPO and human EPO include multiply mutant proteins that have disulfide bonds between Cys₂₉ and Cys₈₈ as well as between
25 Cys₃₃ and Cys₁₃₉. For example, EPO (Cys₂₉-Cys₈₈+Cys₃₃-Cys₁₃₉) has enhanced stability, improved activity, superior pharmacokinetics, improved long-term stability, and significantly enhanced stability in the presence of additional destabilizing mutations.

Human Fc-EPO and human EPO are engineered to have advantageous
30 properties by the introduction of other disulfide bonds. The design of such disulfide bonds can be guided by the known structure of human EPO, which has been determined using X-ray crystallography and NMR. For example, Ala₂₂ and Phe₁₄₂ of human EPO or human Fc-EPO are each replaced by cysteine, and a disulfide bond forms between these new cysteines. To compensate for the empty

volume within the hydrophobic core of the EPO moiety that results from the replacement of Phe₁₄₂ with the smaller cysteine, another nearby amino acid side chain within the hydrophobic core is optimally replaced with a large side chain. For example, Val₇₄ is replaced with Phe, Leu, Tyr, Ile, or Met. The resulting
5 protein with an additional disulfide has enhanced stability, improved activity, superior pharmacokinetics, improved long-term stability, and significantly enhanced stability in the presence of additional destabilizing mutations.

Patent Claims:

1. An erythropoietin (EPO) form having improved properties, wherein said EPO form is
 - 5 (a) a fusion protein comprising a Fc portion of an Ig molecule and an EPO molecule (Fc-EPO), wherein said Fc portion is fused covalently via its C-terminus directly or indirectly to said EPO molecule and wherein the Fc portion as well as the EPO portion may be modified or mutated, selected from the group:
 - 10 (i) Fc - EPO
 - (ii) Fc - L - EPO
 - (iii) Fc - EPO_{desial}
 - (iv) Fc - EPO_m
 - (v) Fc_m - EPO
 - 15 (vi) Fc_m - EPO_m
 - (vii) Fc_m - L - EPO
 - (viii) Fc - L - EPO_m
 - (ix) Fc - EPO_{trunc}
 - (x) Fc - L - EPO_{trunc} wherein
 - 20 EPO is glycosylated, non-glycosylated, partially glycosylated or otherwise modified in its glycosylation pattern;
 EPO_{desial} is EPO which is partially sialylated or non-sialylated;
 EPO_m is EPO which is mutated but not truncated in its amino acid sequence;
 EPO_{trunc} is EPO which is truncated but not mutated in its amino acid
 25 sequence;
 Fc_m is a Fc portion which is mutated and / or truncated in its amino acid sequence and / or modified in its glycosylation pattern, and
 L is linker molecule which has no protease cleavage site,
 or
 - 30 (b) a non-fused human or mammalian EPO or EPO_m having the pattern of cysteines or disulfide bonds that differs from the pattern of cysteines or disulfide bonding of human or mammalian EPO.

2. An EPO form of claim 1, showing improved biological activity.

3. An EPO form of claim 2 having an extended serum half-life
4. An EPO form of claim 3, wherein said extended serum half-life is greater than 20 hours.
5. The fusion proteins (iv), (vi) or (viii) of claim 1, wherein said fusion proteins have greater specific activity than the comparable Fc-EPO fusion proteins having no mutated EPO molecules.
- 10 6. A fusion protein of claim 5, wherein in the EPO_m portion at least one of the following changes is achieved:
Asn_{24, 38, 83} → Gln, Ser₁₂₆ → Ala, His₃₂ → Gly, Ser₃₄ → Arg, Pro₉₀ → Ala.
- 15 7. The fusion proteins (ix) and (x) of claim 1, wherein EPO_{trunc} has an amino acid sequence which ends C-terminally with the amino acid positions 108, 98, 93, 88, 85 or 77 of EPO or EPO_m.
8. A fusion protein of claim 1, wherein the mutation of the Fc_m portion causes reduced affinity to Fc receptors.
- 20 9. A fusion protein of claim 1, wherein the linker L is (Gly₄Ser)_x, x = 1 - 4.
10. A fusion protein of any of the claims 1 - 9, wherein at least one of the cysteine residues of the EPO molecule or EPO_m molecule is engineered.
- 25 11. A fusion protein of claim 10 wherein the EPO moiety has a pattern of disulfide bonding distinct from human or mammalian erythropoietin.
12. A fusion protein of claim 10 or 11 or a non-fused EPO of claim 1, wherein the EPO includes at least one of the following amino acid variations: position 29 is not Cys, position 33 is not Cys, position 88 is Cys, position 139 is Cys.
- 30 13. A fusion protein or a non-fused EPO of any of the claims 10 - 12, wherein said engineered cysteine residues form a disulfide bond.

14. A fusion protein or a non-fused EPO according to claim 12 or 13, wherein the EPO is derived from human EPO and has at least one of the following mutations: His₃₂ → Gly, Ser₃₄ → Arg and Pro₉₀ → Ala.

5 15. A fusion protein according to any of the claims 1 – 14, wherein the EPO portions or EPO_m portions within the Fc fusion protein are dimerized.

16. A fusion protein according to any of the claims 1 – 15, said fusion protein being a whole Ig molecule.

10

17. A fusion protein according to any of the claims 1 – 16, wherein the Ig molecule and the EPO molecule is of mammalian origin.

18. A fusion protein of claim 17, wherein the Ig molecule is human IgG.

15

19. A DNA sequence encoding any of the EPO forms of claims 1 – 18.

20. A DNA molecule encoding a fusion protein of claim 1 comprising:

(a) a signal / leader sequence

20 (b) a Fc region of an Ig molecule

(c) a target protein sequence having the biological activity of erythropoietin.

21. An expression vector comprising a DNA of claim 19 or 20.

25 22. A host cell suitable for expressing an EPO form as defined in claim 1 comprising a vector of claim 21.

23. A method for producing a fusion protein of claim 1, said method comprising:

30 (i) constructing a DNA encoding a precursor protein that comprises from N-terminus to C-terminus a leader sequence for secretion, the Fc portion and the EPO, EPO_m or EPO_{trunc}.


(ii) placing said fused DNA in an appropriate expression vector,

(iii) expressing said fusion protein in a eukaryotic cell, and

(iv) purifying said secreted fusion protein.



24. A pharmaceutical composition comprising an EPO form according to any of the claims 1- 18 and an pharmaceutically acceptable carrier, diluent or excipient.
- 5 25. A pharmaceutical composition of claim 24 containing at least one additional pharmaceutically effective drug and / or adjuvants.

Fig. 1




2/4

Fig. 2



3/4

Fig. 3



4/4

Fig. 4





Fig. 5



1
SEQUENCE LISTING

<110> Merck Patent GmbH

<120> Erythropoietin Forms with Improved Properties

<130> Fc-EPO-LEX-Merck

<140>

<141>

<160> 18

<170> PatentIn Ver. 2.1

<210> 1

<211> 514

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (8)..(505)

<223> Human EPO, DNA sequence modified but no change in
protein sequence

<400> 1

```

cccgggt gcc cca cca cgc ctc atc tgt gac agc cga gtg ctg gag agg 49
    Ala Pro Pro Arg Leu Ile Cys Asp Ser Arg Val Leu Glu Arg
        1             5             10

tac ctc ttg gag gcc aag gag gcc gag aat atc acg acc ggc tgt gct 97
Tyr Leu Leu Glu Ala Lys Glu Ala Glu Asn Ile Thr Thr Gly Cys Ala
    15             20             25             30

gaa cac tgc agc ttg aat gag aac atc acc gtg cct gac acc aaa gtg 145
Glu His Cys Ser Leu Asn Glu Asn Ile Thr Val Pro Asp Thr Lys Val
        35             40             45

aat ttc tat gcc tgg aag agg atg gag gtt ggc cag cag gcc gta gaa 193
Asn Phe Tyr Ala Trp Lys Arg Met Glu Val Gly Gln Gln Ala Val Glu
        50             55             60

gtg tgg cag ggc ctg gcc ctg ctg tcg gaa gct gtc ctg cgg ggc cag 241
Val Trp Gln Gly Leu Ala Leu Leu Ser Glu Ala Val Leu Arg Gly Gln
        65             70             75

gcc ctg ttg gtc aac tct tcc cag ccg tgg gag ccc ctg caa ctg cat 289

```

2

Val Asn Ser Ser Gln Pro Trp Glu Pro Leu Gln Leu His
 80 85 90

gtg gat aaa gcc gtg agt ggc ctc cgc agc ctc acc act ctg ctt cgg 337
 Val Asp Lys Ala Val Ser Gly Leu Arg Ser Leu Thr Thr Leu Leu Arg
 95 100 105 110

gct ctg gga gcc cag aag gaa gcc atc tcc cct cca gat gcg gcc tca 385
 Ala Leu Gly Ala Gln Lys Glu Ala Ile Ser Pro Pro Asp Ala Ala Ser
 115 120 125

gct gct ccc ctc cgc aca atc act gct gac act ttc cgc aaa ctc ttc 433
 Ala Ala Pro Leu Arg Thr Ile Thr Ala Asp Thr Phe Arg Lys Leu Phe
 130 135 140

cga gtc tac tcc aat ttc ctc cgg gga aag ctg aag ctg tac aca ggg 481
 Arg Val Tyr Ser Asn Phe Leu Arg Gly Lys Leu Lys Leu Tyr Thr Gly
 145 150 155

gag gcc tgc cgg aca ggg gac aga tgactcgag 514
 Glu Ala Cys Arg Thr Gly Asp Arg
 160 165

<210> 2

<211> 166

<212> PRT

<213> Homo sapiens

<400> 2

Ala Pro Pro Arg Leu Ile Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu
 1 5 10 15

Leu Glu Ala Lys Glu Ala Glu Asn Ile Thr Thr Gly Cys Ala Glu His
 20 25 30

Cys Ser Leu Asn Glu Asn Ile Thr Val Pro Asp Thr Lys Val Asn Phe
 35 40 45

Tyr Ala Trp Lys Arg Met Glu Val Gly Gln Gln Ala Val Glu Val Trp
 50 55 60

Gln Gly Leu Ala Leu Leu Ser Glu Ala Val Leu Arg Gly Gln Ala Leu
 65 70 75 80

Leu Val Asn Ser Ser Gln Pro Trp Glu Pro Leu Gln Leu His Val Asp
 85 90 95

3

Leu Gly Leu Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu
100 105 110

Gly Ala Gln Lys Glu Ala Ile Ser Pro Pro Asp Ala Ala Ser Ala Ala
115 120 125

Pro Leu Arg Thr Ile Thr Ala Asp Thr Phe Arg Lys Leu Phe Arg Val
130 135 140

Tyr Ser Asn Phe Leu Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Ala
145 150 155 160

Cys Arg Thr Gly Asp Arg
165

<210> 3

<211> 52

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Oligol

<400> 3

ccgggtgccc caccacgcct catctgtgac agccgagtgc tggagaggta cc 52

<210> 4

<211> 49

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: oligo2

<400> 4

tcttggaqgc caaggaggcc gagaatatca cgaccggctg tqctqaaca 49

<210> 5

<211> 52

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Oligo3

ctgcagcttg aatgagaaca tcaccgtgcc tgacaccaaa gtgaatttct at 52

<210> 6

<211> 48

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Oligo4

<400> 6

gcctggaaga ggatggaggt tggccagcag gccgtagaag tgtggcag 48

<210> 7

<211> 51

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Oligo5

<400> 7

ggcctggccc tgctgtcgga agctgtcctg cggggccagg ccctgttggt c 51

<210> 8

<211> 49

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Oligo6

<400> 8

aactcttccc agccgtggga gcccttgcaa ctgcatgtgg ataaagccg 49

<210> 9

<211> 52

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Oligo7

<210> 8

tgagtggcct tgcagccctc accactctgc ttcgggctct gggagcccag aa 52

<210> 10

<211> 48

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Oligo8

<400> 10

ggaagccatc tcccctccag atgcggcctc agctgctccc ctccgcac 48

<210> 11

<211> 53

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Oligo9

<400> 11

aatcactgct gacactttcc gcaaactctt ccgagtctac tccaatttcc tcc 53

<210> 12

<211> 59

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: oligo 10

<400> 12

ggggaaagct gaagctgtac acaggggagg cctgccggac aggggacaga tgactcgag 59

<210> 13

<211> 49

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Oligo11

SEQ ID NO: 1

tcctggaggcc caaggaggcc gagcagatca cgaccggctg tgcctgaaca

49

<210> 14

<211> 52

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Oligol2

<400> 14

ctgcagcttg aatgagcaga tcaccgtgcc tgacaccaaa gtgaatttct at

52

<210> 15

<211> 49

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Oligol3

<400> 15

cagtcctccc agcctggga gccctgcaa ctgcatgtgg ataaagccg

49

<210> 16

<211> 48

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Oligol4

<400> 16

ggaagccatc tccctccag atgcggccgc agctgtccc ctccgcac

48

<210> 17

<211> 232

<212> PRT

<213> Homo sapiens

<220>

<221> PEPTIDE

<222> (1)..(232)

<100> Human IgG1 Fc region-mature protein ⁷

<400> 17

Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala
1 5 10 15

Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro
20 25 30

Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val
35 40 45

Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val
50 55 60

Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln
65 70 75 80

Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln
85 90 95

Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala
100 105 110

Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro
115 120 125

Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr
130 135 140

Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser
145 150 155 160

Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr
165 170 175

Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr
180 185 190

Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe
195 200 205

Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys
210 215 220

Ser Leu Ser Leu Ser Pro Gly Lys
225 230

<210> 18

<211> 326

<212> PRT

<213> Homo sapiens

<220>

<221> PEPTIDE

<222> (1)..(326)

<223> Human IgG2 constant region (CH1, hinge, CH2,
Ch3) - mature protein

<400> 18

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg
1 5 10 15

Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Asn Phe Gly Thr Gln Thr
65 70 75 80

Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys
85 90 95

Thr Val Glu Arg Lys Cys Cys Val Glu Cys Pro Pro Cys Pro Ala Pro
100 105 110

Pro Val Ala Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp
115 120 125

Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
130 135 140

Val Ser His Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly
145 150 155 160

Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn
165 170 175

Ser Thr Phe Arg Val Val Ser Val Leu Thr Val Val His Gln Asp Trp
180 185 190

Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro
195 200 205

Ala Pro Ile Glu Lys Thr Ile Ser Lys Thr Lys Gly Gln Pro Arg Glu
210 215 220

Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn
225 230 235 240

Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
245 250 255

Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
260 265 270

Thr Pro Pro Met Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys
275 280 285

Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys
290 295 300

Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
305 310 315 320

Ser Leu Ser Pro Gly Lys
325